AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
RemeGen cools on DR5
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
